CTLA-4 is an immune checkpoint molecule that downregulates pathways of T cell activation (67), and “Ipilimumab” can inhibit CTLA-4 to improve survival in patients with metastatic melanoma (68). The gene discussed is CTLA4; the disease is metastatic melanoma.